Martin Li

BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.

D. Merico, M. Shago, N. Alon, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.